Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Operating Leases: 2021-2023

Historic Operating Leases for ARS Pharmaceuticals (SPRY) over the last 3 years, with Dec 2023 value amounting to $37,000.

  • ARS Pharmaceuticals' Operating Leases was N/A to $949,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $949,000, marking a year-over-year change of. This contributed to the annual value of $37,000 for FY2023, which is 85.26% down from last year.
  • According to the latest figures from FY2023, ARS Pharmaceuticals' Operating Leases is $37,000, which was down 85.26% from $251,000 recorded in FY2022.
  • ARS Pharmaceuticals' Operating Leases' 5-year high stood at $480,000 during FY2021, with a 5-year trough of $37,000 in FY2023.
  • Moreover, its 3-year median value for Operating Leases was $251,000 (2022), whereas its average is $256,000.
  • Data for ARS Pharmaceuticals' Operating Leases shows a maximum YoY crashed of 85.26% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows ARS Pharmaceuticals' Operating Leases stood at $480,000 in 2021, then tumbled by 47.71% to $251,000 in 2022, then tumbled by 85.26% to $37,000 in 2023.